The immuno-oncology assays market encompasses a range of diagnostic and research products designed to evaluate the immune response to cancer therapies. These assays include flow cytometry panels, multiplexed ELISA platforms, next-generation sequencing panels, and spatial biology kits that detect biomarkers such as PD-L1, CTLA-4, and tumor-infiltrating lymphocytes. By offering high sensitivity, specificity, and throughput, these assays accelerate drug development and enable personalized treatment selection.
Researchers and clinicians rely on these tools for immunoprofiling, monitoring treatment response, and identifying novel therapeutic targets. The advantages of immuno-oncology assays—such as reduced assay time, multiplex capability, and integration with bioinformatics—address critical market needs for precise and rapid insights.
Global Immuno-Oncology Assays Market size is estimated to be valued at USD 5.55 Bn in 2025 and is expected to reach USD 11.82 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 11.4% from 2025 to 2032.
Key Takeaways
Key players operating in the Immuno-Oncology Assays Market are Charles River Laboratories, F. Hoffmann-La Roche Ltd, Illumina, Inc., Agilent Technologies, Inc., Thermo Fisher Scientific Inc., Merck KGaA, Invivoscribe, Inc., QIAGEN, PerkinElmer Inc., Sartorius AG, Bio-Rad Laboratories, Inc., Bruker Spatial Biology, Inc., Nexelis, Reaction Biology, Crown Bioscience, HTG Molecular Diagnostics, Inc., Axion BioSystems, Inc., and BioTherapeutics LLC.
Market drivers
Immuno-Oncology Assays Market size is the increasing adoption of immunotherapies and targeted treatments for cancer. As immune checkpoint inhibitors and CAR-T cell therapies demonstrate clinical success, there is an urgent need for companion diagnostics to guide patient selection and monitor therapeutic efficacy. This driver is underscored by the growing emphasis on biomarker-driven treatment protocols, which depend on accurate quantification of immune markers. Furthermore, the rise in clinical trials evaluating novel immuno-oncology agents is fueling demand for high-throughput, multiplex assay platforms.
PEST Analysis
Political: In response to the critical need for targeted oncology diagnostics, regulatory bodies in North America, Europe and key parts of Asia have implemented expedited review pathways and collaborative public–private initiatives that encourage transparent data sharing, streamline approval processes for novel assays, and offer grant incentives—thereby strengthening the policy environment for immuno‐oncology assay development and commercialization.
Economic: Rising health care budgets alongside increased investment from both private equity and governmental research grants are underpinning extensive R&D activities aimed at refining assay precision and throughput; furthermore, growing emphasis on value‐based reimbursement models is reshaping procurement frameworks, unlocking substantial market opportunities and influencing long‐term business growth strategies.
Social: Heightened patient advocacy for personalized cancer care, coupled with growing public awareness of immuno‐oncology benefits, is fostering collaborative outreach programs and driving adoption of advanced diagnostic assays, while sociocultural shifts in digital engagement and community forums are influencing industry share by highlighting emerging biomarkers and encouraging proactive screening.
Geographical Concentration by Value
North America has long maintained a dominant position in the global Immuno‐Oncology Assays Market, commanding the largest market share thanks to robust healthcare infrastructure, advanced clinical trial networks and generous funding initiatives. Comprehensive reimbursement frameworks and an established regulatory environment have provided a solid foundation for assay adoption, reinforcing attractive market dynamics. Additionally, Europe registers significant contributions in value, driven by growing cancer research hubs in Germany, the UK and France, as well as harmonized regulatory standards that facilitate cross‐border collaborations. Meanwhile, highly developed laboratory networks in Japan and Australia have bolstered Asia Pacific’s secondary foothold, enriched by partnerships between academic institutions and biotechnology firms. This concentration of value offers critical market insights into regional priorities and investment focuses, guiding companies in shaping their regional allocation plans.
Fastest‐Growing Region
Asia Pacific is emerging as the fastest growing territory within the Immuno‐Oncology Assays domain, propelled by surging investments in biotechnological research, supportive governmental policies and an expanding patient population. In particular, public funding programs and tax incentives across several APAC countries are catalyzing local assay manufacturing and validation studies, while cross‐border partnerships with academic research centers are enabling technology transfers that enhance assay robustness.
Get this Report in Japanese Language
Get this Reports in Korean Language
Read More Articles Related to this Industry-EHR Software Development: Ultimate Guide for 2025
About Author:
Priya Pandey is a dynamic and passionate editor with over three years of expertise in content editing and proofreading. Holding a bachelor's degree in biotechnology, Priya has a knack for making the content engaging. Her diverse portfolio includes editing documents across different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. Priya's meticulous attention to detail and commitment to excellence make her an invaluable asset in the world of content creation and refinement.
(LinkedIn- https://www.linkedin.com/in/priya-pandey-8417a8173/)